Differential regulation of central BDNF protein levels by antidepressant and non-antidepressant drug treatments.

Brain Research
Darrick T BaluIrwin Lucki

Abstract

Antidepressant treatments have been proposed to produce their therapeutic effects, in part, through increasing neurotrophin levels in the brain. The current experiments investigated the effects of acute and chronic treatment with different pharmacologic and somatic antidepressant treatments on protein levels of BDNF in several brain regions associated with depression in the rat. Repeated applications (10 days) of electroconvulsive shock (ECS), but not a single treatment (1 day), produced 40-100% increases of BDNF protein in the hippocampus, frontal cortex, amygdala, and brainstem. Chronic (21 days), but not acute (1 day), treatment with the tricyclic antidepressant (TCA) desipramine (10 mg/kg), the selective serotonin reuptake inhibitor (SSRI) fluoxetine (10 mg/kg), and the monoamine oxidase inhibitor (MAOI) phenelzine (10 mg/kg) increased BDNF protein levels in the frontal cortex (10-30%), but not in the hippocampus, amygdala, olfactory bulb, and brain stem. To determine whether the regulation of BDNF was unique to antidepressant treatments, drugs used to treat schizophrenia and anxiety were also studied. Chronic administration of the typical antipsychotic haloperidol (1 mg/kg) and the atypical antipsychotic clozapine (20 mg/k...Continue Reading

References

Sep 12, 1995·Proceedings of the National Academy of Sciences of the United States of America·M KorteT Bonhoeffer
Oct 27, 1995·Science·H Thoenen
Oct 28, 1998·Proceedings of the National Academy of Sciences of the United States of America·D OngürJ L Price
Apr 15, 1999·Annual Review of Neuroscience·A K McAllisterD C Lo
Jan 14, 2000·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·K FujimakiR S Duman
Jun 7, 2000·Proceedings of the National Academy of Sciences of the United States of America·A J EischE J Nestler
Jun 23, 2000·Biological Psychiatry·T M MadsenA Tingström
Dec 24, 2002·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·Haiyun XuXin-Min Li
Feb 25, 2003·Annual Review of Neuroscience·Rosalind A Segal
May 3, 2003·Neuropharmacology·A L CoppellT S C Zetterström
Feb 4, 2005·The Journal of Neuroscience : the Official Journal of the Society for Neuroscience·Mikko SairanenEero Castrén
Jul 23, 2005·The International Journal of Neuropsychopharmacology·Raffaella MolteniMarco Andrea Riva
Dec 6, 2005·Experimental Brain Research·Yong-Mei ZhongKathleen S Rockland
Dec 27, 2005·General Hospital Psychiatry·Trevor J SchraufnagelPeter P Roy-Byrne
Mar 11, 2006·Neuron Glia Biology·Sarina B ElmariahRita J Balice-Gordon
Apr 25, 2006·Biological Psychiatry·Ronald S Duman, Lisa M Monteggia
May 25, 2006·Frontiers in Bioscience : a Journal and Virtual Library·Eberhard FuchsBoldizsar Czeh
Jun 27, 2006·Biological Psychiatry·Alex Dranovsky, René Hen
Dec 21, 2006·Journal of Clinical Pharmacy and Therapeutics·I R De Oliveira, M F Juruena
May 22, 2007·CNS & Neurological Disorders Drug Targets·G Rajkowska, J J Miguel-Hidalgo
Jun 26, 2007·Biological Psychiatry·Mounira BanasrRonald S Duman

❮ Previous
Next ❯

Citations

Sep 1, 2011·Pharmaceutical Research·Siva Ram Kiran VakaMichael A Repka
Jan 14, 2009·Molecular Psychiatry·S Couillard-DespresL Aigner
Jan 30, 2009·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·Darrick T BaluIrwin Lucki
Sep 11, 2009·Pharmacogenetics and Genomics·Katrin SangkuhlRuss B Altman
Oct 16, 2009·The Journal of Pharmacology and Experimental Therapeutics·Georgia E HodesIrwin Lucki
Mar 13, 2012·Pharmacological Reviews·Anita E Autry, Lisa M Monteggia
Oct 30, 2013·Molecular Psychiatry·M D OpalS M Dulawa
Jan 21, 2015·Progress in Neuro-psychopharmacology & Biological Psychiatry·Luana M ManossoAna Lúcia S Rodrigues
Oct 17, 2013·Journal of Neuropathology and Experimental Neurology·Ludmyla KandrataviciusJoao Pereira Leite
Jan 28, 2012·Pharmacology & Therapeutics·Sivasankaran Balaratnasingam, Aleksandar Janca
Aug 18, 2010·Experimental Neurology·Laura BaroncelliLamberto Maffei
Jul 20, 2010·Journal of Ethnopharmacology·Seungjoo LeeJong Hoon Ryu
Feb 23, 2010·International Journal of Developmental Neuroscience : the Official Journal of the International Society for Developmental Neuroscience·Jinsook KimAlexei Kondratyev
Jun 23, 2009·Pharmacology & Therapeutics·Raffaella MolteniMarco Andrea Riva
Nov 6, 2008·Behavioural Brain Research·Smita Thakker-Varia, Janet Alder
Sep 16, 2015·Translational Psychiatry·M B YoungL L Howell
Oct 15, 2013·Progress in Neuro-psychopharmacology & Biological Psychiatry·Li-Tao YiDi Wu
Jun 12, 2013·Neuropharmacology·Ipe Ninan
Feb 16, 2013·Progress in Neuro-psychopharmacology & Biological Psychiatry·Mee-Sook SongGlen B Baker

❮ Previous
Next ❯

Related Concepts

Related Feeds

Amygdala: Sensory Processes

Amygdalae, nuclei clusters located in the temporal lobe of the brain, play a role in memory, emotional responses, and decision-making. Here is the latest research on sensory processes in the amygdala.

Antipsychotic Drugs

Antipsychotic drugs are a class of medication primarily used to manage psychosis (including delusions, hallucinations, paranoia or disordered thought), principally in schizophrenia and bipolar disorder. Discover the latest research on antipsychotic drugs here

Amygdala and Midbrain Dopamine

The midbrain dopamine system is widely studied for its involvement in emotional and motivational behavior. Some of these neurons receive information from the amygdala and project throughout the cortex. When the circuit and transmission of dopamine is disrupted symptoms may present. Here is the latest research on the amygdala and midbrain dopamine.